Comparison of Bleeding Risk Between Rivaroxaban and Apixaban for the Treatment of Acute Venous Thromboembolism
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
Apixaban and rivaroxaban have been compared to standard therapy for treatment of acute
symptomatic venous thromboembolism (VTE) in randomized controlled trials (RCTs), and are both
approved by Health Canada. No safety or efficacy data is available from direct head-to-head
comparison of these two anticoagulants. Lawsuits in the United States over bleeding events,
patient perceptions, and concerns with medication adherence are additional factors
highlighting the importance of a comparison trial. This multi-center, pragmatic, prospective,
randomized, open-label, blinded end-point (PROBE) trial aims to compare the safety of
apixaban and rivaroxaban for the treatment of VTE.
Phase:
Phase 4
Details
Lead Sponsor:
Ottawa Hospital Research Institute
Collaborators:
Canadian Institutes of Health Research (CIHR) Canadian Venous Thromboembolism Clinical Trials and Outcomes Research (CanVECTOR) Network